CF
VRDN icon

Corebridge Financial’s Viridian Therapeutics VRDN Stock Holding History

Corebridge Financial’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,556
Closed -$493K – 2726
2025
Q1 		$493K Buy
36,556
+220
+0.6% +$3.75K ﹤0.01% 1608
2024
Q4 		$697K Buy
36,336
+2,878
+9% +$62.6K ﹤0.01% 1504
2024
Q3 		$761K Sell
33,458
-206
-0.6% -$3.37K ﹤0.01% 1505
2024
Q2 		$438K Buy
+33,664
New +$466K ﹤0.01% 1765

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Corebridge Financial's VRDN Position: Q2 2025 in Review

Corebridge Financial sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 36,556 shares — an estimated $493K sold.

Corebridge Financial first reported a position in VRDN in Q2 2024 and held it in 4 quarters. The position peaked at $761K in Q3 2024. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

  • Corebridge Financial reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 36,556 Viridian Therapeutics shares in Q2 2025, an estimated $493K.
  • Corebridge Financial first reported a position in Viridian Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Viridian Therapeutics position peaked at $761K in Q3 2024.
  • 170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.